← Back to headlines
FDA Grants Fast Track Designation to Kymera Therapeutics' KT-621
The U.S. Food and Drug Administration has granted Fast Track designation to Kymera Therapeutics, Inc.'s KT-621 for the treatment of eosinophilic asthma. This designation aims to expedite the development and review of drugs for serious conditions.
24 Apr, 13:41 — 24 Apr, 13:41
Sources
Showing 1 of 1 sources
